Home > Resources > Whitepapers > Machine Learning, Artificial Intelligence, and Systems Biology: A New Way to Interrogate

Machine Learning, Artificial Intelligence, and Systems Biology: A New Way to Interrogate

December 1, 2016

Remarkable innovations in the technologies that generate ‘omics data have swiftly created such profound efficiencies that the cost of next-generation sequencing (NGS) has fallen below $1,000 per genome. This has led to the creation of vast amounts of data. The challenge of how to harness this rich information, and from it harvest practicable therapeutics, has been thrust to the forefront of advanced analytics.It is anticipated that in the upcoming decade genomics data will require more computing resources than the data demand from astronomy.

Spotlight

Kymanox

Leveraging our experienced team and intellectual assets, we provide a broad range of technical services and products. Our core competencies include Project Management, Quality and Compliance.

OTHER WHITEPAPERS

Biopharmaceutical Sector

whitePaper | May 29, 2023

tronger than expected US inflation and a bump in consumer spending have fuelled worldwide expectations that interest rates will go higher, as predictions about future monetary policy rapidly shift.

Bispecific Antibodies Unleashed from Mechanisms to Manufacturing and Strategic Collaboration for Effective Precision Immunotherapy

whitePaper | July 13, 2023

Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising therapeutic potential such that their applicability to a variety of therapies is being explored.

Quality Control Solutions for Cell and Gene Therapy

whitePaper | September 10, 2022

Droplet Digital PCR (ddPCR) provides highly precise and absolute quantification of nucleic acids by counting nucleic acid molecules encapsulated in discrete water-in-oil droplets.

Are Nitrosamines a Concern for Biologic Manufacturers?

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.

The EU Clinical Trials Regulation − What You Need to Know

whitePaper | March 22, 2022

The Clinical Trials Regulation has retained some definitions and refined others. For example the definition of “clinical study”: “Any investigation in relation to humans intended: (a) to discover or verify the clinical, pharmacological or other pharmacodynamic.

Advanced Biopharmaceutical Manufacturing: An Evolution Underway

whitePaper | June 5, 2022

The past decade has seen a significant shift in the nature of the products being manufactured and sold by the innovative biopharmaceutical (biopharma) industry. The global biopharmaceutical portfolio of today reflects increased therapeutic competition, a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise of treatments for many orphan diseases.